利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.026 秒)

    Anti-obesity agents
    2.
    发明申请
    Anti-obesity agents 失效
    抗肥胖剂

    公开(公告)号：US20050176643A1

    公开(公告)日：2005-08-11

    申请号：US11067556

    申请日：2005-02-25

    申请人： Dominique Bridon ,  Roger Leger ,  Xicai Huang ,  Karen Thibaudeau ,  Martin Robitaille ,  Peter Milner

    发明人： Dominique Bridon ,  Roger Leger ,  Xicai Huang ,  Karen Thibaudeau ,  Martin Robitaille ,  Peter Milner

    IPC分类号： A61K38/17 ,  C07K7/08

    CPC分类号： C07K14/57545 ,  A61K38/00 ,  C07K19/00 ,  C07K2319/01

    摘要： The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

    摘要翻译： 本发明涉及包含与反应性基团偶联的PYY肽或其功能性衍生物的化合物。 这样的反应性基团能够对血液成分进行反应，与其形成稳定的共价键。 本发明还涉及包含共价键合到血液成分上的化合物的缀合物。 此外，本发明还涉及在患者中增强PYY肽或其功能性衍生物的抗肥胖活性的方法。

    Method of treatment of diabetes and/or obesity with reduced nausea side effect
    6.
    发明申请
    Method of treatment of diabetes and/or obesity with reduced nausea side effect 失效
    减少恶心副作用的糖尿病和/或肥胖症的治疗方法

    公开(公告)号：US20070207958A1

    公开(公告)日：2007-09-06

    申请号：US11595576

    申请日：2006-11-09

    申请人： Dominique Bridon ,  Jean-Paul Castaigne ,  Karen Thibaudeau

    发明人： Dominique Bridon ,  Jean-Paul Castaigne ,  Karen Thibaudeau

    IPC分类号： A61K38/22

    CPC分类号： A61K38/26 ,  A61K47/643

    摘要： The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.

    摘要翻译： 本发明提供以有效治疗病症或病症的量施用促胰岛素肽的方法，同时通过向有需要的受试者施用与白蛋白缀合的促胰岛素肽来减轻恶心副作用。 本发明还提供了选择用于给予共轭促胰岛素肽的受试者的方法。 用促胰岛素肽治疗的示例性疾病或病症包括肥胖症和II型糖尿病。

    Affinity markers for human serum albumin
    9.
    发明申请
    Affinity markers for human serum albumin 失效
    人血清白蛋白的亲和标记

    公开(公告)号：US20050037974A1

    公开(公告)日：2005-02-17

    申请号：US10934841

    申请日：2004-09-02

    申请人： Alexander Krantz ,  Wolin Huang ,  Arthur Hanel ,  Darren Holmes ,  Dominique Bridon

    发明人： Alexander Krantz ,  Wolin Huang ,  Arthur Hanel ,  Darren Holmes ,  Dominique Bridon

    IPC分类号： A61K38/00 ,  A61K47/48 ,  A61K49/00 ,  C07K14/665 ,  A61K38/08 ,  C07K7/06

    CPC分类号： A61K49/0021 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6901 ,  A61K49/0043 ,  A61K49/0056 ,  C07K14/665

    摘要： Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-Ca—R—Cb-A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, Ca and Cb are connector groups between E and R and between R and A, respectively, and A is a group having an affinity for human serum albumin, wherein affinity group A comprises a sequence of amino acid residues —O1—O2—X1—X2—B in which the amino acid residues are independently selected from the group of all twenty naturally occurring amino acids. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.

    摘要翻译： 提供了用于鉴定与靶分子具有亲和力或互补性的化合物的方法和组合物。 根据本发明的化合物可以由式E-Ca-R-Cb-A描述，其中E是治疗或诊断剂，R是反应性基团，Ca和Cb是E和R之间的连接基团，R和 A，A是对人血清白蛋白具有亲和性的基团，其中亲和基团A包含氨基酸残基-O1-O2-X1-X2-B的序列，其中氨基酸残基独立地选自 的二十种天然存在的氨基酸。 根据本发明的化合物可以用于标记靶分子，特别是当目标分子天然存在于复杂混合物如生理液体如血液中时。 通过体内亲和标记，生理活性实体的寿命可以通过与长寿命的血液成分结合而大大增强。 共价结合的实体也可以用作特异性结合蛋白的拮抗剂或激动剂或作为酶抑制剂。